Litifilimab

Summary

Litifilimab (CHEMBL3833308) is a phase-3 clinical-stage antibody targeting CLEC4C; indicated across 3 conditions including cutaneous lupus erythematosus and systemic lupus erythematosus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (CLEC4C)
• Indications: 3 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833308
Name	Litifilimab
Type	Antibody
Max phase	3

Also known as: 24F4A, Biib 059, BIIB-059, Biib059, BIIB059, Litifilimab, anti-BDCA2, LITIFILIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CLEC4C	C-type lectin domain family 4 member C	Binding		0%	Q8WTT0

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CLEC4C.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Dectin-2 family	1	CLEC4C
Neutrophil degranulation	1	CLEC4C

Dominant GO biological processes

GO term	Targets
adaptive immune response	1
antifungal innate immune response	1
immune system process	1
innate immune response	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cutaneous lupus erythematosus	3	MONDO:0005282	EFO:0003834
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915
autoimmune disease	2	MONDO:0007179	EFO:0005809

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	4
PHASE1	3
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04895241	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919	PHASE3	ENROLLING_BY_INVITATION	An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05531565	PHASE2/PHASE3	RECRUITING	A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337	PHASE3	ENROLLING_BY_INVITATION	A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT02847598	PHASE2	COMPLETED	Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
NCT02106897	PHASE1	COMPLETED	Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
NCT03224793	PHASE1	COMPLETED	Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
NCT06741657	PHASE1	COMPLETED	A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).